IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hateboer et al.

Serial No.: To be assigned

Filed: March 1, 2004

For: RECOMBINANT PROTEIN PRODUCTION IN A HUMAN CELL

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 2578-4038.3US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV326919672US

Date of Deposit with USPS: _____ March 1, 2004

Person making Deposit: ___ Christopher Haughton

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

U.S. Patent Documents

U.S. Patent No.	Publication Date	<u>Patentee</u>	
*US - 5,994,128	11-30-1999	Fallaux et al.	
*US - 6,653,101 B1	11/25/2003	Cockett et al.	

Foreign Patent Documents

Document No.	Publication Date	<u>Patentee</u>
*WO 93/03163	02-18-1993	Fond Nat Transfusion
*WO 97/00326	01-03-1997	Univ Leiden
*WO 95/29994	11-09-1995	Univ Michigan
*EP 0 185 573	06-25-1986	Pasteur Institut

Other Documents

^{*}PCT International Search Report, PCT/NL00/00247, dated October 9, 2000, 3 pages.

^{*}GHOSH-CHOUDHURY et al., Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of the full length genomes, The EMBO Journal, 1987, pp. 1733-39, Vol. 6, No. 6.

^{*}LOUIS et al., Cloning and Sequencing of the Cellular--Viral Junctions from the Human Adenovirus Type 5 Transformed 293 Cell Line, Virology, 1997, pp. 423-29, Vol. 233.

^{*}NCBI Entrez Nucleotide accession number U38242.

^{*}NCBI Entrez Nucleotide accession number NC_002018.

^{*}NCBI Entrez Nucleotide accession number X02996 J01967 J01968 J01970 J01971 J01972 J01974 J01976 J01977 J01978 J01979 K00515 V00025 V00026 V00027 V00029.

Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are <u>not</u> being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/549,463 Filed: April 14, 2000

For: RECOMBINANT PROTEIN PRODUCTION IN A HUMAN CELL, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

*SETOGUCHI et al., "Stimulation of Erythropoiesis by in vivo gene therapy: Physiologic consequences of transfer of the humanerythropoietin gene to experimental animals using an adenovirus vector," Blood, November 1, 1994, pp. 2946-53, Vol. 84, No. 9.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56 & 1.175, applicant hereby identifies the following listed copending applications naming the same inventor(s):

Attorney Docket No.:

2183-4075US

Serial No.:

09/332,803

Filing Date:

6/14/1999

Title:

PACKAGING SYSTEMS FOR HUMAN RECOMBINANT

ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.:

2578-4123.2US

Serial No.:

09/348,354

Filing Date:

7/7/1999

Title:

CHIMAERIC ADENOVIRUSES

Attorney Docket No.:

2183-4231US

Serial No.:

09/444,284

Filing Date:

11/19/1999

Title:

GENE DELIVERY VECTORS PROVIDED WITH A TISSUE

TROPISM FOR SMOOTH MUSCLE CELLS, AND/OR

ENDOTHELIAL CELLS

Attorney Docket No.:

2183-4240US

Serial No.:

09/449,854

Filing Date:

11/26/1999

Title:

PRODUCTION OF VACCINES

Attorney Docket No.:

2183-4038.1US

Serial No.:

09/549,463

Filing Date:

4/14/2000

Title:

RECOMBINANT PROTEIN PRODUCTION IN A HUMAN CELL

Attorney Docket No.:

2183-3982.2US

Serial No.:

09/517,898 3/3/2000

Filing Date: Title:

MEANS AND METHODS FOR FIBROBLAST-LIKE OR

MACROPHAGE-LIKE CELL TRANSDUCTION

Attorney Docket No.:

2183-4070.1US 09/573,740

Serial No.: Filing Date:

5/18/2000

Title:

Title:

SEROTYPES OF ADENOVIRUS AND USES THEREOF

Attorney Docket No.:

2183-4497US

Serial No.:

09/621,593 7/21/2000

Filing Date:

MEANS AND METHODS FOR RAISING ANTIBODY

CONCENTRATION IN COMPARTMENTS OF THE BODY OF A

NON HUMAN ANIMAL

Attorney Docket No.:

2183-4192.1US

Serial No.:

09/657,492

Filing Date:

9/8/2000

Title:

MODIFIED ADENOVIRAL VECTORS FOR USE IN GENE

THERAPY

Attorney Docket No.:

2578-4489US 09/665,472

Serial No.: Filing Date:

9/20/2000

Title:

GENE DELIVERY VECTORS PROVIDED WITH A TISSUE

TROPISM FOR DENDRITIC CELLS

Attorney Docket No.:

2183-4626US

Serial No.:

09/722,867

Filing Date:

11/27/2000

Title:

PRODUCTION OF VACCINES

Attorney Docket No.:

2183-4843US

Serial No.:

09/843,894 4/27/2001

Filing Date: Title:

AAV VECTOR PRODUCTION

Attorney Docket No.:

2578-3840.1US 09/900,062

Serial No.: Filing Date:

7/6/2001

Title:

PACKAGING SYSTEMS FOR HUMAN RECOMBINANT

ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.:

2578-3833.5US 09/918,029

Serial No.: Filing Date:

7/30/2001

Title:

PACKAGING SYSTEMS FOR HUMAN RECOMBINANT

ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.:

2578-4509.1US

Serial No.: Filing Date:

09/928,262 8/10/2001

Title:

GENE DELIVERY VECTORS WITH CELL TYPE SPECIFICITY

FOR PRIMARY HUMAN CHONDROCYTES

Attorney Docket No.:

2578-4123.1US

Serial No.:

09/953,280

Filing Date:

9/14/2001

Title:

CHIMAERIC ADENOVIRUSES

Attorney Docket No.:

2183-5006.1US

Serial No.:

10/010,645

Filing Date:

11/13/2001

Title:

GENE DELIVERY VECTORS WITH CELL TYPE SPECIFICITY

FOR MESENCHYMAL STEM CELLS

Attorney Docket No.:

2578-3833.6US

Serial No.:

10/038,271

Filing Date:

10/23/2001

Title:

PACKAGING SYSTEMS FOR HUMAN RECOMBINANT

ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.:

2578-3833.7US

Serial No.:

10/125,751

Filing Date:

4/18/2002

Title:

PACKAGING SYSTEMS FOR HUMAN RECOMBINANT

ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.:

2578-3955.1US 10/136,139

Serial No.: Filing Date:

Serial No.:

5/1/2002

Title:

MEANS AND METHODS FOR NUCLEIC ACID DELIVERY

VEHICLE DESIGN AND NUCLEIC ACID TRANSFER

Attorney Docket No.:

2578-4451.1US 10/196,688 7/15/2002

Filing Date: Title:

ADENO-ASSOCIATED VIRUS AND ADENOVIRUS CHIMERIC RECOMBINANT VIRUSES USEFUL FOR THE INTEGRATION

OF FOREIGN GENETIC INFORMATION INTO CHROMOSOMAL DNA OF TARGET CELLS

Attorney Docket No.:

2578-3833.8US

Serial No.:

10/219,414 8/15/2002

Filing Date: Title:

STOCKS OF REPLICATION DEFICIENT ADENOVIRUS

Attorney Docket No.:

2578-4215.1US 10/231,735

Serial No.: Filing Date:

8/28/2002

Title:

INTERLEUKIN-3 GENE THERAPY FOR CANCER

Attorney Docket No.:

2578-4038.2US 10/234,007

Serial No.: Filing Date:

9/3/2002

Title:

RECOMBINANT PROTEIN PRODUCTION IN A HUMAN

CELL

Attorney Docket No.:

2578-5592US 10/305,435 11/25/2002

Serial No.: Filing Date:

Title:

METHODS AND MEANS FOR ENHANCING SKIN

TRANSPLANTATION USING GENE DELIVERY VEHICLES HAVING TROPISM FOR PRIMARY FIBROBLASTS, AS WELL AS OTHER USES THEREOF (PRIMAIRE FIBROBLASTEN)

Attorney Docket No.:

2578-5832US

Serial No.:

10/381,088 3/20/2003

Filing Date: Title:

ADENOVIRAL VECTORS PROVIDED WITH A TROPISM FOR

DENDRITIC CELLS

Attorney Docket No.:

2578-5904US

Serial No.:

10/381,857

Filing Date:

8/13/2003

Title:

ADENOVIRAL VECTORS FOR GENE DELIVERY IN

SKELETAL MUSCLE CELLS OR MYOBLASTS

Attorney Docket No.:

2578-3840.2US

Serial No.:

10/396,548

Filing Date:

3/25/2003

Title:

PACKAGING SYSTEMS FOR HUMAN RECOMBINANT

ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.:

2578-3833.9US

Serial No.:

10/618,526

Filing Date:

7/11/2003

Title:

PACKAGING SYSTEMS FOR HUMAN RECOMBINANT

ADENOVIRUS TO BE USED IN GENE THERAPY

Attorney Docket No.:

2578-6077US

Serial No.:

10/644,256

Filing Date:

8/20/2003

Title:

EFFICIENT PRODUCTION OF IgA IN RECOMBINANT

MAMMALIAN CELLS

Attorney Docket No.:

2578-6158US

Serial No.:

10/698,086

Filing Date:

10/30/2003

Title:

METHODS FOR THE IDENTIFICATION OF ANTIVIRAL

COMPOUNDS

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits.

Respectfully submitted,

Andrew F. Nilles

Registration No. 47,825 Attorney for Applicant(s)

TRASKBRITT, PC

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: March 1, 2004

ACT/bv

Enclosures: Form PTO-1449 or PTO/SB/08

Document in ProLaw

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute f	for form 1449A/PTO				Complete if Known	
	INFO	RMATION	DI	SCLOSURE	Application Number	To be assigned	
STATEMENT BY APPLICANT		Filing Date	March 1, 2004				
		EMENT D		I I BIOZH I	First Named Inventor	Hateboer et al.	
					Group Art Unit	To be assigned	
		(use as many she	ets as	necessary)	Examiner Name	To be assigned	
	Sheet	1	of	2	Attorney Docket Number	2578-4038.3US	

U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant		
Initials *	No.1	Number - Kind Code ² (if known)	MM-DD-YYYY		Passages or Relevant Figures Appear		
		*US-5,994,128	11-30-1999	Fallaux et al.			
		*US-6,653,101 B1	11/25/2003	Cockett et al.			
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-			_		
		US-					
		US-					
		US-					
	T	US-					
_		US-					
	I	US-					
		US-					
		US-					
		US-					

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
_		*WO 93/03163	02-18-1993	Fond Nat Transfusion		
_		*WO 97/00326	01-03-1997	Univ Leiden		
		*WO 95/29994	11-09-1995	Univ Michigan		
		*EP 0 185 573	06-25-1986	Pasteur Institut		
				-		

Examiner Signature	•	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

-						
	Substitute fo	or form 1449A/PTO				Complete if Known
	INEO		INI	COLOCUDE	Application Number	To be assigned
				SCLOSURE	Filing Date	March 1, 2004
	STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Hateboer et al.
					Group Art Unit	To be assigned
		(use as many she	ets as	necessary)	Examiner Name	To be assigned
	Sheet	2	of	2	Attorney Docket Number	2578-4038.3US

l)
ckaging
ed 293
1978
e , Vol.
th

Examiner	Date	
Signature	 Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Serial No.: 09/549,463 Filed: April 14, 2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

^{*}Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

For: RECOMBINANT PROTEIN PRODUCTION IN A HUMAN CELL, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.